NeuroPace (NPCE) EBITDA Margin Growth (3y) (2023 - 2026)
NeuroPace (NPCE) EBITDA Margin Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -201.00 |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 586.00 |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 736.00 |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 887.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 963.00 |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 212.00 |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 535.00 |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 244.00 |
| 10 | NeuroPace | 478.49 Mn | 426.79 Mn | 18.91 Mn | 2,504.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,504.00 |
| Mar 31, 2026 | 3,225.00 |
| Dec 31, 2025 | 7,044.00 |
| Sep 30, 2025 | 8,191.00 |
| Jun 30, 2025 | 7,857.00 |
| Mar 31, 2025 | 6,298.00 |
| Dec 31, 2024 | 6,496.00 |
| Sep 30, 2024 | 4,024.00 |
| Jun 30, 2024 | 411.00 |
| Mar 31, 2024 | -709.00 |
| Dec 31, 2023 | -32.00 |
| Sep 30, 2023 | -2,709.00 |
| Jun 30, 2023 | -247.00 |
| Mar 31, 2023 | -277.00 |